Close this search box.

DNA Script bags US$200m financing

Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.

Paris and San Francisco-based biotech company DNA Script has completed a Series C financing, raising $200m of new capital. With this latest financing, DNA Script has raised $315m since the company was founded in 2014. T. Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC, Columbia Threadneedle Investments, Casdin Capital, as well as other investors who participated in the first closing of $165m.

The company announced it will use the proceeds from the funding to advance its SYNTAX Platform, an on-demand enzymatic printing technology funded by the US DARPA in order to develop a prototype device for rapid mobile nucleic acid manufacturing for US RNA vaccine specialist Moderna Inc. 

“SYNTAX is the first step toward creating a new paradigm for DNA and RNA synthesis”, said DNA Script’s Co-founder and CEO Thomas Ybert. The company’s alternative to traditional DNA synthesis is called Enzymatic DNA Synthesis, or EDS, and run on the SYNTAX instrument.